The inhibition of miR-122 protects hepatocytes from lipid metabolic disorders such as NAFLD and suppresses lipogenesis via elevating SIRT1 and activating the AMPK pathway [297]. This evidence concerns the gene SIRT1 and metabolic dysfunction-associated steatotic liver disease.